YAVNE, Israel , July 16, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, will host an analyst day on its innovative product for chronic wounds on Monday,
YAVNE, Israel , June 11, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the appointment of Mr.
Avalon Pharmaceutical Peru S.A.C., MediWound’s exclusive distributor, plans commercial launch for first half of 2020 YAVNE, Israel , June 04, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in
Total non-dilutive funds for NexoBrid now valued at up to $196 Million MediWound to initiate NexoBrid expanded access treatment protocol (NEXT) in the third quarter of 2019, allowing for ongoing use of NexoBrid to treat burn patients in U.S. YAVNE, Israel , May 29, 2019 (GLOBE NEWSWIRE) --
Met Primary and All Secondary Endpoints in Pivotal Phase 3 DETECT Study; NexoBrid BLA Filing Planned for Fourth Quarter of 2019 Signed Exclusive License Agreement with Vericel for Commercial Rights to NexoBrid ® in North America Conference call begins today at 8:30 a.m.
YAVNE, Israel , May 14, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the first
$17.5 million upfront, sales royalties and up to $132.5 million in potential milestones Leverages Vericel’s Commercial Capabilities and Presence in U.S. Burn Care Market Biologics License Application (BLA) Filing Planned for Fourth Quarter of 2019 Company to Host a Conference Call Today at 8:00 am
YAVNE, Israel , March 26, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD ), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that it has filed its annual report on Form 20-F for the fiscal
Met Primary and All Secondary Endpoints in its Pivotal Phase 3 Study (DETECT) in NexoBrid ® for Eschar Removal of Severe Thermal Burns Awarded Additional BARDA Contract Valued up to $43 Million for the Development of NexoBrid for Sulfur Mustard Injuries Conference call begins today at 8:30 a.m.
YAVNE, Israel , March 18, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the fourth
